Embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference
Embecta | 10-K: FY2024 Annual Report
BTIG Maintains Embecta(EMBC.US) With Buy Rating, Maintains Target Price $26
BTIG Upgrades Embecta Corporation (EMBC) to a Buy
Embecta To Go Ex-Dividend On December 6th, 2024 With 0.15 USD Dividend Per Share
Embecta Corp Appoints Anthony Roth as VP and CAO
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley Upgrades Embecta to Equalweight, Price Target Is $20
Embecta Upgraded to Equal Weight From Underweight at Morgan Stanley
Is It Time To Consider Buying Embecta Corp. (NASDAQ:EMBC)?
This Dick's Sporting Goods Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday
Embecta Price Target Raised to $20 From $17 at BofA
Express News | Embecta Corp : Btig Raises to Buy From Neutral
BTIG Upgrades Embecta to Buy, Announces $26 Price Target
Embecta Analyst Ratings
Morgan Stanley Maintains Embecta(EMBC.US) With Sell Rating, Maintains Target Price $13
BTIG Upgrades Embecta(EMBC.US) to Buy Rating, Announces Target Price $26
Embecta Corporation: Discontinued Patch Pump Program and Financial Shortfalls Prompt Sell Rating
Embecta Corporation's Strategic Shifts and Revenue Outlook Prompt 'Sell' Rating
Unlock the Full List